Results 161 to 170 of about 2,071 (176)

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis

British Journal of Clinical Pharmacology, 2017
Sophie Glatt
exaly  

Bimekizumab-bkzx

Clinical Therapeutics
openaire   +2 more sources

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

Lancet, The, 2020
Joseph F Merola, Arthur Kavanaugh, Georg Schett   +2 more
exaly  

Bimekizumab effective across the axSpA spectrum

Nature Reviews Rheumatology, 2023
openaire   +2 more sources

Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study

Journal of the American Academy of Dermatology, 2020
Christopher Griffiths, Joseph F Merola, Kim A Papp   +2 more
exaly  

Bimekizumab safe and effective for psoriatic arthritis

Nature Reviews Rheumatology, 2023
openaire   +2 more sources

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F

Frontiers in Immunology, 2020
exaly  

Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review

Annals of Pharmacotherapy
Steven Feldman, Shannon Moran
exaly  

Bimekizumab for the treatment of psoriatic arthritis

Expert Review of Clinical Immunology
Yoshiya Tanaka
exaly  

Bimekizumab Effective on Skin and Joints

International Journal of Dermatology
Thomas Herzinger, Sonja C. Molin
openaire   +2 more sources